Zilebesiran is an investigational RNA interference therapeutic agent being developed by Roche and Alnylam Pharmaceuticals for the treatment of hypertension. From Wikipedia
The KARDIA-2 results in JAMA pave the way for trials to assess effects on heart attacks, strokes and cardiovascular death.
